Biotechnology

After gaining FDA alignment, INmune Bio is advancing its inflammation-targeting drug, XPro1595, offering a novel and potentially safer approach for patients.

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

BioNexus Gene Lab appoints Matthew Barsing to lead its Chemrex subsidiary, signaling a strategic overhaul from industrial chemicals to biotech and advanced tech.

A lucrative deal for a rare disease voucher positions Fortress Biotech for profitability, highlighting a successful strategy and a breakthrough for Menkes patients.

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

New federal initiatives are fast-tracking deep brain stimulation research, a move championed by Nexalin Technology that could revolutionize care for veterans.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

At a key industry summit, Sutro Biopharma showcases its next-gen ADC platform, designed to overcome treatment resistance with "supercharged" dual-payload drugs.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

A Malaysian biotech's new study shows its NK cell therapy is safe, using a novel, low-cost method that could make advanced cancer treatment affordable worldwide.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

A brief delay in Avidity's stockholder vote signals the final, complex steps before its acquisition by Novartis and the launch of a new spin-off.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

After halting all R&D, PCI Biotech proposes dissolution and delisting, marking the end for its novel drug delivery platform and a warning for investors.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

With stellar trial data and a fast-tracked FDA submission, CG Oncology prepares for a pivotal presentation at the TD Cowen Health Care Conference.

iRegene Therapeutics hits dual milestones, advancing AI-derived cell therapies for Parkinson's in the US and Multiple System Atrophy in China.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.